Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Lung Cancer

Interventions

RADIATION: Ablative Radiation
DRUG: Durvalumab
DRUG: Etoposide
DRUG: Carboplatin

Sponsor

University of Chicago